EIF1AX mutations are detected in approximately 14% of thyroid cancers, with reported frequencies of 11% in poorly differentiated thyroid cancer (PDTC) and 9% in anaplastic thyroid cancer (ATC) [25]. This evidence concerns the gene EIF1AX and thyroid gland undifferentiated (anaplastic) carcinoma.